Huntington Ingalls Industries, Inc. (HII)
Live price chart, market sentiment, and community perspectives for Huntington Ingalls Industries, Inc. (NYSE: HII).
Live price chart, market sentiment, and community perspectives for Huntington Ingalls Industries, Inc. (NYSE: HII).
On our desk, we are closely tracking the Diamond Hill Capital Mid Cap Strategy letter from Q2 2026 regarding HII. Even though the narrative highlights ongoing margin pressure, the fundamental tailwinds and market placement keep it highlighted as a core stock to watch. Sentiment remains cautiously optimistic across mid-cap portfolios despite periodic session pullbacks.
Reviewing the latest Q1 2026 earnings reports, HII posted an EPS slightly beating estimates, though the stock faced mixed signals and initial declines. Pretax income reports indicate operational resilience, but risk managers need to account for immediate price friction as shares trade around $277.25 with support holding underneath.
As a quant analyst looking at alternative data models, Danelfin's proprietary AI model assigns HII a maximum score of 10/10 today, placing it squarely in the Strong Buy category. When prepping internal models or pitching quantitative allocations, this technical alignment provides a powerful counter-weight to fundamental margin debates.
Watching the 50-day MA and recent price action, HII dipped roughly 0.98% down to $277.25 in the latest session, yet it continues to hold key support levels. Institutional interest remains robust, making it a recurring topic for long-term holders looking at core industrial selections for 2026.
Looking at 24/7 Wall St.'s updated modeling, our twelve-month target price sits at $368.07, while other forecasts project movement up to $352.16 over the next 52 weeks. Risk desks are mapping these targets against current macroeconomic variables to evaluate optimal entry points following recent minor session dips.
Parsing the Q2 2026 numbers, HII delivered an absolute beat by reporting $5.27 EPS on $3.4B in revenue, outpacing expectations by 38.3%. However, despite this massive earnings beat, Financhill assigns a more modest stock score of 35/100, reflecting a stark divergence between headline performance and algorithmic risk scoring.
Explore plasma cleansing, somatic organ swaps, and BCI.